Literature DB >> 21342144

Anticardiolipin antibodies in patients with Behcet's disease.

Maja Zivkovic1, Marko Zlatanovic, Gordana Zlatanovic, Jasmina Djordjevic-Jocic, Sonja Cekic.   

Abstract

The aims of this study are to determine anticardiolipin antibodies in patients with Sy Behcet and to determine correlation between the levels of anticardiolipin antibodies in serum in patients with clinic systemic and ocular manifestations. The study was conducted on 11 patients with Behcet disease (group I), and on 11 healthy subjects (group II). Anticardiolipin antibodies -aCL were determined by the standard ELISA method, where 1GPL= 1 microgram/ml IgG aCL and 1 MPL= 1 microgram/ ml IgM, and were considered negative < 10 GPL or MPL, low positive (10-40 GPL and MPL), or high positive (>40 GPL and MPL). In the group of 11 patients with the diagnosis Sy Behcet, 6 of them were (54.5%) with values of anticardiolipin antibodies over 10 positive. In the control group of the healthy examinees aCl were positive in 2 cases (18.2%). There are no statistically significant differences in the presence of systemic clinic characteristics between aCl positive and negative patients. All the patients with SY Behcet in whom anticardiolipn antibodies were found have extremely severe visual damage which is not present in the group of those patients where the values of aCl were low. The difference is statistically significant. The level of anticardiolipin antibodies is increased in the patients with Behcet. There are no statistically significant differences in the presence of systemic clinical characteristics between aCL positive and negative patients. Visual acuity in patients with SY Behcet is statistically significantly much lower in patients who had increased values of aCL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342144      PMCID: PMC4362568          DOI: 10.17305/bjbms.2011.2625

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  20 in total

1.  Occlusive retinal vasculitis associated with systemic lupus erythematosus.

Authors:  R W Read; L P Chong; N A Rao
Journal:  Arch Ophthalmol       Date:  2000-04

2.  Is there a role for anti-phospholipid-binding protein antibodies in the pathogenesis of thrombosis in Behcet's disease?

Authors:  R Priori; F Conti; V Pittoni; T Garofalo; M Sorice; G Valesini
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

Review 3.  Behçet's disease.

Authors:  Adriana A Bonfioli; Fernando Orefice
Journal:  Semin Ophthalmol       Date:  2005 Jul-Sep       Impact factor: 1.975

Review 4.  Anticardiolipin antibodies and ocular disease.

Authors:  Filipe Vieira Lima Cabrita; C Stephen Foster
Journal:  Ocul Immunol Inflamm       Date:  2005 Jul-Aug       Impact factor: 3.070

Review 5.  Current concepts in the etiology and treatment of Behçet disease.

Authors:  Cem Evereklioglu
Journal:  Surv Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 6.048

6.  Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus.

Authors:  A Montehermoso; R Cervera; J Font; M Ramos-Casals; M García-carrasco; F Formiga; J L Callejas; M Jorfán; M C Griñó; M Ingelmo
Journal:  Semin Arthritis Rheum       Date:  1999-04       Impact factor: 5.532

7.  Elevated soluble Fas in aqueous humor of patients with Behcet's uveitis: correlation with uveitis severity.

Authors:  Wan-Uk Kim; Sang-Moon Chung; Tae-Won Han; Woo-Jin Sah; Min-Ho Kim
Journal:  Jpn J Ophthalmol       Date:  2002 Jan-Feb       Impact factor: 2.447

8.  Catastrophic antiphospholipid syndrome in a patient with Behçet's disease.

Authors:  Giuseppe Famularo; Salvatore Antonelli; Annalisa Barracchini; Maurizio Menichelli; Giulio Cesare Nicotra; Giovanni Minisola
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

9.  Anticardiolipin antibodies in uveitis.

Authors:  A M Klok; R Geertzen; A Rothova; G S Baarsma; A Kijlstra
Journal:  Curr Eye Res       Date:  1992       Impact factor: 2.424

Review 10.  Managing the symptoms of Behçet's disease.

Authors:  Cem Evereklioglu
Journal:  Expert Opin Pharmacother       Date:  2004-02       Impact factor: 3.889

View more
  5 in total

1.  Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment.

Authors:  Fatmazohra Djaballah-Ider; Abdelhamid Djaballah; Zineb Djeraba; Samia Chaib; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2019-02-05       Impact factor: 4.473

2.  Behcet's Disease: New Concepts in Cardiovascular Involvements and Future Direction for Treatment.

Authors:  M B Owlia; G Mehrpoor
Journal:  ISRN Pharmacol       Date:  2012-03-08

Review 3.  An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions.

Authors:  Giacomo Emmi; Elena Silvestri; Danilo Squatrito; Lucia Ciucciarelli; Anna Maria Cameli; Gentian Denas; Mario Milco D'Elios; Vittorio Pengo; Lorenzo Emmi; Domenico Prisco
Journal:  ScientificWorldJournal       Date:  2014-10-14

4.  Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis.

Authors:  Md Asiful Islam; Sayeda Sadia Alam; Shoumik Kundu; A H M Safayet Ullah Prodhan; Shahad Saif Khandker; Tatiana Reshetnyak; Przemysław J Kotyla; Rosline Hassan; Tareq Hossan
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

Review 5.  Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

Authors:  Elias Manca
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-11       Impact factor: 10.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.